- Scalable collaboration for biotech and pharma teams: Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing
- Integrated, AI-ready biologics ecosystem: Connects design to execution through native Signals One platform integration and cloud-native infrastructure
- Unified molecular cloning workflows: Supports Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis in one platform
WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration.
The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals OneTM platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem.
“The Signals BioDesign offering addresses a critical need for molecular biology teams developing the next generation of antibody, cell, and gene therapies,” said Kevin Willoe, president of Revvity Signals Software. “This solution empowers researchers with enterprise-ready collaboration and centralized construct management without the complexity of over-engineered platforms. By integrating directly with our Signals One platform, we’re focusing on enabling teams to accelerate therapeutic development timelines and bring life-saving treatments to patients faster.”
The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design.
Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Contacts
Investor Relations:
Steve Willoughby
[email protected]
Media Relations:
Chet Murray
(781) 462-5126
[email protected]
